• Capricor Therapeutics posted a net loss of USD 33.9 million, or USD 0.59 per share, in Q1 2026, widening from a net loss of USD 24.4 million, or USD 0.53 per share, a year earlier.
• Total operating expenses climbed to USD 36.8 million from USD 25.0 million year over year, while revenue remained at no revenue.
• Cash, cash equivalents and marketable securities fell to USD 278.6 million as of March 31, 2026, from USD 318.1 million at year-end 2025, with runway expected into Q4 2027.
• Deramiocel BLA remained under active FDA review with a PDUFA target action date of Aug. 22, 2026, while the HOPE-3 Phase 3 trial met its primary endpoint and all Type I error-controlled secondary endpoints.
• Management said labeling discussions are expected to start soon, with commercial launch preparations underway and stockpiling planned once label guidance is received.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capricor Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605121605PRIMZONEFULLFEED9718754) on May 12, 2026, and is solely responsible for the information contained therein.